GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York

GenSight Biologics Reports Full Year 2018 Financial Results

GenSight Biologics Reports its Cash Position as of March 31, 2019

GenSight Biologics completes a capital increase of €8 million without discount subscribed entirely by Sofinnova

GenSight Biologics Updates its 2019 Financial Calendar

BioEurope Spring, Vienna, Austria

GenSight Biologics Announces its 2019 Financial Calendar

GenSight Biologics Reports its Cash Position as of December 31, 2018